Abstract
Lamivudine, adefovir, telbivudine, and entecavir are nucleoside analogues that can inhibit hepatitis B virus replication and are licensed in China by the Food and Drug Administration. This study presents the cases of 2 patients who were chronically infected with HBV and suffered hepatic failure resulting from withdrawal of telbivudine and adefovir, respectively.
MeSH terms
-
Adenine / adverse effects
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Adult
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Guanine / adverse effects
-
Guanine / analogs & derivatives
-
Guanine / therapeutic use
-
Hepatitis B, Chronic / drug therapy
-
Hepatitis B, Chronic / pathology*
-
Histocytochemistry
-
Humans
-
Lamivudine / adverse effects
-
Lamivudine / therapeutic use*
-
Liver Failure, Acute / etiology*
-
Liver Failure, Acute / pathology
-
Liver Failure, Acute / virology*
-
Liver Transplantation
-
Male
-
Medication Adherence
-
Necrosis
-
Organophosphonates / adverse effects
-
Organophosphonates / therapeutic use*
-
Telbivudine
-
Thymidine / adverse effects
-
Thymidine / analogs & derivatives
-
Thymidine / therapeutic use
Substances
-
Antiviral Agents
-
Organophosphonates
-
Telbivudine
-
Lamivudine
-
entecavir
-
Guanine
-
adefovir
-
Adenine
-
Thymidine